Skip to main content

Medication Treatments

Kloxxado, a new nasal spray product that delivers 8 mg of naloxone to treat opioid overdose—double the 4 mg found in Narcan—has received FDA approval.
Preliminary data from researchers at the University of Pittsburgh Medical Center showed that naltrexone reduced both pain and disability in chronic pain patients when administered in low doses, according to a media report.
A study by researchers at Oregon Health & Science University and the Oregon State University College of Pharmacy found that 1 in 5 pharmacies refuse to dispense Suboxone, the medication that combines buprenorphine and naloxone.
The Department of Health and Human Services announced on Tuesday it is releasing a new version of its Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that will allow nearly all prescribers to treat opioid use disorder with buprenorphine.
Concurrent with a rise in opioid overdose deaths, fewer new patients received buprenorphine prescriptions for the treatment of opioid use disorder during the early months of the COVID-19 pandemic, according to researchers at Princeton University.
Back to Top